TRPV1拮抗剂SJP-0132治疗干眼病的随机双盲安慰剂对照1/2期研究结果
这项1/2期随机双盲安慰剂对照研究在干眼病患者中评估了TRPV1拮抗剂SJP-0132的安全性、耐受性、药代动力学和疗效。研究显示SJP-0132安全且耐受性良好,血浆浓度呈剂量依赖性增加,疗效数据表明其可改善干眼病的体征和症状且起效迅速。
要点
- SJP-0132安全且耐受性良好,所有治疗中出现的不良事件均为轻度。
- 血浆浓度呈剂量依赖性增加,眼干VAS在首次给药后30分钟即下降。
- 角膜荧光素染色评分在整个治疗期间下降,呈与VAS相似的剂量依赖性。
核心结论
- SJP-0132安全且耐受性良好,血浆浓度呈剂量依赖性增加,疗效数据表明其改善干眼病的体征和症状且起效迅速。
研究设计与样本
- 1/2期、随机、双盲、单中心、安慰剂对照的单次和多次递增剂量研究。
- 纳入年龄≥18岁、患者报告干眼病史≥6个月、眼干VAS≥40 mm、DEQ-5≥6、中央角膜荧光素染色2至4(Baylor量表)的一般健康成人。
- A部分包含四个单次递增剂量队列,B部分包含两个多次递增剂量队列。
- A部分在每个队列中按1:3随机接受单次安慰剂或SJP-0132,B部分按1:2随机接受安慰剂或SJP-0132每日四次共4周。
主要发现
- A部分和B部分分别随机29例和60例参与者。
- A部分接受SJP-0132的21例中有2例、B部分接受SJP-0132的40例中有6例报告至少一次治疗中出现的不良事件,安慰剂组分别为8例中0例和20例中7例。
- 所有治疗中出现的不良事件均为轻度。
- A部分0.1%和0.3%组以及B部分0.3%组在首次给药后30分钟眼干VAS即下降,下降持续整个治疗期,但与安慰剂相比无统计学显著性。
- 角膜荧光素染色评分在整个治疗期间下降,呈与VAS相似的剂量依赖性。
关键数值与推荐
- 主要结局为不良事件数量和严重程度、血浆浓度、第29天4小时眼干VAS较基线平均变化以及第29天中央区CFS评分。
- 次要终点包括所有5区总CFS、结膜染色、泪膜破裂时间、其他干眼症状VAS、DEQ-5和泪液基质金属蛋白酶-9。
临床怎么用
- SJP-0132在干眼病患者中安全且耐受性良好,并显示出改善体征和症状的快速起效趋势。
- 研究结果为后续更大规模临床试验评估SJP-0132治疗干眼病的疗效提供了初步依据。
局限性
- 眼干VAS下降与安慰剂相比无统计学显著性。
- 研究为单中心、样本量较小的1/2期研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the safety, tolerability, pharmacokinetic profile, and efficacy of SJP-0132 in participants with dry eye disease (DED). DESIGN: Phase 1/2, randomized, double-masked, single-center, placebo-controlled single and multiple ascending dose study. PARTICIPANTS: Generally healthy adults aged ≥18 years with a patient-reported history of DED for ≥6 months, eye dryness visual analog scale (VAS: 0-100) ≥40 mm, 5-item dry eye questionnaire (DEQ-5) ≥6, and central corneal fluorescein staining (CFS) of 2 to 4 (Baylor scale: 0-5 for each of five zones). METHODS: This study consisted of Part A and Part B, containing four single- and two multiple-ascending dose cohorts, respectively. Following a 14-day placebo run-in, participants were randomized 1:3 to receive a single dose of placebo or SJP-0132 in each cohort in Part A. In Part B, participants were randomized 1:2 to receive placebo or SJP-0132 four times daily for 4 weeks in each cohort. MAIN OUTCOME MEASURES: The primary outcomes were the number and severity of adverse events, plasma concentration, and mean change from baseline in eye dryness VAS at 4 hours on Day 29 and in CFS score at the central zone on Day 29. Secondary end points included total CFS of all 5 zones, conjunctival staining, tear film break-up time, additional dry eye symptom VAS, DEQ-5, and tear matrix metalloproteinase-9. RESULTS: Twenty-nine and 60 participants were randomized to Part A and B, respectively. Two of 21 and 6 of 40 participants who received SJP-0132 in each part reported at least one treatment-emergent adverse event (TEAE), compared with 0 of 8 and 7 of 20 for placebo. All TEAEs were mild. Plasma concentrations increased dose dependently. Eye dryness VAS decreased as early as 30 minutes after the first dose in the 0.1% and 0.3% groups in Part A and in the 0.3% group in Part B. The decrease persisted throughout the treatment period, although it was not statistically significant versus placebo. CFS scores decreased throughout the treatment period with a dose dependence similar to VAS. CONCLUSIONS: SJP-0132 was safe and well tolerated, plasma concentrations increased dose dependently, and efficacy data indicated that it improved both signs and symptoms of DED with a rapid onset of improvement.
引用
- Wada T, Omatsu K, Pflugfelder SC, et al. Results of a Randomized, Double-Masked, Placebo-Controlled Phase 1/2 Study of a TRPV1 Antagonist SJP-0132 in Participants With Dry Eye Disease. Am J Ophthalmol. 2026. PMID: 41554419. doi:10.1016/j.ajo.2026.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。